CDXS Codexis

Codexis to Hold Second Quarter 2020 Conference Call on August 6

Codexis to Hold Second Quarter 2020 Conference Call on August 6

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.

We encourage participants to pre-register for the conference call using the following link: . Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Those without internet access or unable to pre-register may dial in by calling:

U.S.866-777-2509
International412-317-5413
Passcode10146500

A live webcast of the call will be available at . The webcast will be archived for 90 days.

A replay of the call will be available for 48 hours by calling:

 U.S.877-344-7529
Canada855-669-9658
International412-317-0088
Passcode10146500
The replay will be available for 48 hours

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to discover, develop and commercialize proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals, industrial enzymes, enzymes for use in molecular biology, diagnostics and other life science applications, and enzymes and other proteins as biotherapeutics. Codexis’ proven technology platform delivers value by enabling highly targeted and application-relevant improvements in protein performance. For more information, see .

Contact:

LHA Investor Relations

Jody Cain, 310-691-7100

EN
30/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

 PRESS RELEASE

Codexis Achieves ISO 9001:2015 Certification

Codexis Achieves ISO 9001:2015 Certification REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The official certification reflects Codexis’s dedication to delivering manufacturing excellence by applying a high standard of quality assurance throughout all of its processes, including research and development, product manufacturing and testing, delivery, support, and customer service. “Quality ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis Announces Signing of Lease for GMP Manufacturing Facility REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modific...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch